MA32943B1 - Piperidine spiro pyrrolidione et piperidinone substituees, leur preparation et leur utilisation therapeutique - Google Patents

Piperidine spiro pyrrolidione et piperidinone substituees, leur preparation et leur utilisation therapeutique

Info

Publication number
MA32943B1
MA32943B1 MA33987A MA33987A MA32943B1 MA 32943 B1 MA32943 B1 MA 32943B1 MA 33987 A MA33987 A MA 33987A MA 33987 A MA33987 A MA 33987A MA 32943 B1 MA32943 B1 MA 32943B1
Authority
MA
Morocco
Prior art keywords
substituted
treatment
biperidenone
biperiden
spiro
Prior art date
Application number
MA33987A
Other languages
Arabic (ar)
English (en)
Inventor
Zhongli Gao
Daniel Hall
Ryan Hartung
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Sa filed Critical Sanofi Sa
Publication of MA32943B1 publication Critical patent/MA32943B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4468—Non condensed piperidines, e.g. piperocaine having a nitrogen directly attached in position 4, e.g. clebopride, fentanyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Anesthesiology (AREA)
  • Obesity (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

LA PRÉSENTE INVENTION CONCERNE UNE SÉRIE DE CARBOXAMIDES DE N-PHÉNYL-BIPYRROLIDINE SUBSTITUÉS DE FORMULE (I) DANS LAQUELLE: R1, R2, M, N ET P SONT TELS QUE DÉFINIS DANS LA DESCRIPTION. D'UNE MANIÈRE PLUS SPÉCIFIQUE, LES COMPOSÉS SELON L'INVENTION SONT DES MODULATEURS DES RÉCEPTEURS DE H3 ET SONT DONC UTILES EN TANT QU'AGENT PHARMACEUTIQUES, NOTAMMENT DANS LE TRAITEMENT ET/OU LA PRÉVENTION DE DIVERSES MALADIES MODULÉES PAR LES RÉCEPTEURS DE H3 COMPRENANT LES MALADIES ASSOCIÉES AU SYSTÈME CENTRAL NERVEUX. EN OUTRE, LA PRÉSENTE INVENTION CONCERNE ÉGALEMENT DES PROCÉDÉS DE PRÉPARATION DE CARBOXAMIDES DE N-PHÉNYL-BIPYRROLIDINE SUBSTITUÉS ET DES INTERMÉDIAIRES UTILISÉS À CET EFFET.
MA33987A 2008-12-05 2009-12-04 Piperidine spiro pyrrolidione et piperidinone substituees, leur preparation et leur utilisation therapeutique MA32943B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US12008808P 2008-12-05 2008-12-05
FR0955431 2009-07-31
PCT/US2009/066673 WO2010065803A1 (fr) 2008-12-05 2009-12-04 Pipéridine spiro pyrrolidinone et pipéridinones substitués utilisés comme modulateurs de h3

Publications (1)

Publication Number Publication Date
MA32943B1 true MA32943B1 (fr) 2012-01-02

Family

ID=41647030

Family Applications (1)

Application Number Title Priority Date Filing Date
MA33987A MA32943B1 (fr) 2008-12-05 2009-12-04 Piperidine spiro pyrrolidione et piperidinone substituees, leur preparation et leur utilisation therapeutique

Country Status (24)

Country Link
US (2) US8227481B2 (fr)
EP (1) EP2373652B1 (fr)
JP (1) JP5538421B2 (fr)
KR (1) KR101687216B1 (fr)
CN (1) CN102239168B (fr)
AR (1) AR074466A1 (fr)
AU (1) AU2009322248B2 (fr)
CA (1) CA2745721C (fr)
CO (1) CO6390058A2 (fr)
CR (1) CR20110294A (fr)
DK (1) DK2373652T3 (fr)
EC (1) ECSP11011108A (fr)
ES (1) ES2441221T3 (fr)
IL (1) IL213290A (fr)
MA (1) MA32943B1 (fr)
MX (1) MX2011004939A (fr)
NZ (1) NZ593151A (fr)
PE (1) PE20120261A1 (fr)
PT (1) PT2373652E (fr)
RU (1) RU2011127401A (fr)
TN (1) TN2011000233A1 (fr)
TW (1) TWI481609B (fr)
WO (1) WO2010065803A1 (fr)
ZA (1) ZA201103448B (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR074467A1 (es) 2008-12-05 2011-01-19 Sanofi Aventis Tetrahidropiran espiro pirrolidinonas y piperidinonas sustituidas, composiciones farmaceuticas que las contienen y uso de las mismas en el tratamiento y/o prevencion de enfermedades del snc ,tales como alzheimer y parkinson, entre otras.
TW201206939A (en) * 2010-05-11 2012-02-16 Sanofi Aventis Substituted phenyl cycloalkyl pyrrolidine (piperidine) spirolactams and amides, preparation and therapeutic use thereof
JP5833105B2 (ja) 2010-05-11 2015-12-16 サノフイ 置換ｎ−ヘテロアリールスピロラクタムビピロリジン類、その製造及び治療的使用
JP2013526530A (ja) * 2010-05-11 2013-06-24 サノフイ 置換されたｎ−フェニルスピロラクタムビピロリジン、その製造及び治療上の使用
WO2011143162A1 (fr) 2010-05-11 2011-11-17 Sanofi Carboxamides de n-hétéroaryl-bipyrrolidine substitués, leur préparation et leur utilisation thérapeutique
TW201206910A (en) 2010-05-11 2012-02-16 Sanofi Aventis Substituted N-heterocycloalkyl bipyrrolidinylphenyl amide derivatives, preparation and therapeutic use thereof
AR081034A1 (es) 2010-05-11 2012-05-30 Sanofi Aventis Derivados de n-heteroaril tetrahidro-isoquinolina sustituidos, composiciones farmaceuticas que los contienen y uso de los mismos para el tratamiento de enfermedades del sistema nervioso central
JP5766278B2 (ja) 2010-05-11 2015-08-19 サノフイ 置換されたｎ−アルキルおよびｎ−アシルテトラヒドロ−イソキノリン誘導体、それらの製造および治療上の使用
CA2887348A1 (fr) 2012-10-11 2014-04-17 Merck Sharp & Dohme Corp. Composes spiropiperidinyliques substitues utiles comme agonistes de gpr120
US9197285B2 (en) * 2012-12-20 2015-11-24 Deere & Company Methods and apparatus for ameliorating signal reception
US11192891B2 (en) 2017-11-03 2021-12-07 Bristol-Myers Squibb Company Diazaspiro ROCK inhibitors

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3256276A (en) 1961-02-17 1966-06-14 Geschickter Fund Med Res Substituted spiroimides
FR2816940A1 (fr) 2000-11-23 2002-05-24 Lipha Derives de 4-(biphenylcarbonylamino)-piperidine, compositions les contenant et leur utilisation
CA2493458A1 (fr) * 2002-07-24 2004-01-29 Ptc Therapeutics, Inc. Composes d'acide benzoique a substitution ureido et leur utilisation pour la suppression de non-sens et le traitement de maladie
WO2004037257A1 (fr) * 2002-10-23 2004-05-06 Janssen Pharmaceutica, N.V. Phenylpiperidines et phenylpyrrolidines utilisees comme modulateurs du recepteur h3 de l'histamine
DE10306250A1 (de) * 2003-02-14 2004-09-09 Aventis Pharma Deutschland Gmbh Substituierte N-Arylheterozyklen, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
US7223788B2 (en) 2003-02-14 2007-05-29 Sanofi-Aventis Deutschland Gmbh Substituted N-aryl heterocycles, process for their preparation and their use as medicaments
JP4524550B2 (ja) 2003-08-19 2010-08-18 オイレス工業株式会社 摺動部材用樹脂組成物および摺動部材
WO2005028438A1 (fr) 2003-09-22 2005-03-31 Banyu Pharmaceutical Co., Ltd. Nouveau derive de piperidine
BRPI0608653A2 (pt) * 2005-04-01 2010-11-30 Lilly Co Eli composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, e, uso de um composto ou um sal do mesmo
TW200804382A (en) 2005-12-05 2008-01-16 Incyte Corp Lactam compounds and methods of using the same
AU2006326067A1 (en) * 2005-12-16 2007-06-21 F. Hoffmann-La Roche Ag Pyrrolo [2 , 3-b] pyridine derivatives as H3 receptor modulators
JP5175228B2 (ja) * 2006-02-15 2013-04-03 サノフイ 新規なアザシクリル置換アリールジヒドロイソキノリノン、それらの製造方法及び薬剤としてそれらの使用
US20080247964A1 (en) 2006-05-08 2008-10-09 Yuelian Xu Substituted azaspiro derivatives
WO2008002820A2 (fr) 2006-06-29 2008-01-03 Janssen Pharmaceutica N.V. Composés de benzylamine substituée
WO2008142859A1 (fr) * 2007-05-18 2008-11-27 Kowa Company, Ltd. Nouveau composé spiro-oxindole et produit pharmaceutique le contenant
CL2008001839A1 (es) 2007-06-21 2009-01-16 Incyte Holdings Corp Compuestos derivados de 2,7-diazaespirociclos, inhibidores de 11-beta hidroxil esteroide deshidrogenasa tipo 1; composicion farmaceutica que comprende a dichos compuestos; utiles para tratar la obesidad, diabetes, intolerancia a la glucosa, diabetes tipo ii, entre otras enfermedades.
WO2009039431A2 (fr) * 2007-09-21 2009-03-26 Neurogen Corporation Amines spirocycliques aryl-condensées substituées
PL2212283T3 (pl) 2007-10-17 2012-01-31 Sanofi Sa Podstawione karboksyamidy N-fenylobipirolidyny i ich zastosowanie terapeutyczne
MX2010004003A (es) 2007-10-17 2010-04-30 Sanofi Aventis N-fenil-pirrolidinilmetlipirrolidin amidas sustituidas y uso terapeutico de las mismas.
CN101903339B (zh) * 2007-10-17 2012-06-27 赛诺菲-安万特 取代的n-苯基-联吡咯烷羧酰胺及其治疗用途
CN102317289A (zh) 2008-11-23 2012-01-11 辉瑞大药厂 作为β分泌酶抑制剂的内酰胺
AR074467A1 (es) 2008-12-05 2011-01-19 Sanofi Aventis Tetrahidropiran espiro pirrolidinonas y piperidinonas sustituidas, composiciones farmaceuticas que las contienen y uso de las mismas en el tratamiento y/o prevencion de enfermedades del snc ,tales como alzheimer y parkinson, entre otras.

Also Published As

Publication number Publication date
IL213290A (en) 2014-01-30
JP2012511012A (ja) 2012-05-17
CA2745721A1 (fr) 2010-06-10
KR20110100639A (ko) 2011-09-14
CO6390058A2 (es) 2012-02-29
AU2009322248B2 (en) 2015-07-16
DK2373652T3 (da) 2014-01-20
TW201036974A (en) 2010-10-16
ES2441221T3 (es) 2014-02-03
MX2011004939A (es) 2011-05-25
EP2373652A1 (fr) 2011-10-12
US20120258979A1 (en) 2012-10-11
PE20120261A1 (es) 2012-04-04
AU2009322248A1 (en) 2011-06-23
KR101687216B1 (ko) 2016-12-16
ZA201103448B (en) 2012-01-25
WO2010065803A1 (fr) 2010-06-10
TN2011000233A1 (en) 2012-12-17
CR20110294A (es) 2011-09-21
RU2011127401A (ru) 2013-01-10
TWI481609B (zh) 2015-04-21
CA2745721C (fr) 2013-09-24
CN102239168A (zh) 2011-11-09
JP5538421B2 (ja) 2014-07-02
NZ593151A (en) 2012-11-30
EP2373652B1 (fr) 2013-10-09
US8227481B2 (en) 2012-07-24
PT2373652E (pt) 2014-01-16
IL213290A0 (en) 2011-07-31
US20110257213A1 (en) 2011-10-20
US8604046B2 (en) 2013-12-10
CN102239168B (zh) 2014-03-12
AR074466A1 (es) 2011-01-19
ECSP11011108A (es) 2011-11-30

Similar Documents

Publication Publication Date Title
MA32943B1 (fr) Piperidine spiro pyrrolidione et piperidinone substituees, leur preparation et leur utilisation therapeutique
DK2212283T3 (da) Substituerede N-phenylbipyrrolidincarboxamider og terapeutisk anvendelse deraf
EA201001126A1 (ru) Пирролопиримидины и пирролопиридины
EA201190217A1 (ru) Замещенные 2-ацетамидо-5-арил-1,2,4-триазолоны и их применение
MX2010009752A (es) Compuestos de oxadiazoantraceno para el tratamiento de diabetes.
EA201001639A1 (ru) Композиции и способы их получения и применения
ATE530524T1 (de) Substituierte sulfonamid-derivate
EA201500182A1 (ru) 4-МЕТИЛ-2,3,5,9,9b-ПЕНТААЗАЦИКЛОПЕНТА[a]НАФТАЛИНЫ
DK2212282T3 (da) Substituerede N-phenylbipyrrolidincarboxamider og terapeutisk anvendelse deraf
MX2010003948A (es) N-fenil-birrolidin ureas sustituidas y uso terapeutico de las mismas.
MA32505B1 (fr) 5-alcynyl-pyrimidines
EA200970065A1 (ru) Производные пиперазинила, предназначенные для лечения заболеваний, опосредованных рецептором gpr38
ATE430744T1 (de) Thiazolylpiperidin-derivate nützlich als h3 rezeptor modulatoren
MX2010004003A (es) N-fenil-pirrolidinilmetlipirrolidin amidas sustituidas y uso terapeutico de las mismas.
MA32945B1 (fr) Tétrahydropyrane spiro pyrrolidinone et pipéridinone substituées, leur préparation et leur utilisation thérapeutique
ATE466854T1 (de) 1h-indol-6-ylpiperazin-1-ylmethanonderivate zur verwendung als h3-rezeptormodulatoren
EA200970849A1 (ru) Трициклические производные изохинолина для лечения ожирения
EA201190003A1 (ru) Производные хроменона в качестве trpv3 антагонистов
TH149042A (th) การเตรียมเตตระไฮโดรไพแรน สไปโร ไพโรลิดิโนนที่ถูกแทนที่ และพิเพอริดิโนน และการใช้ประโยชน์ในการรักษาของมัน
EA200601842A1 (ru) D-гомо-17-хлор-16(17)-ен-стероиды